AstraZeneca
$156.90Change from previous close: −0.51%Absolute change: −$0.80
At a glance
- Revenue growth
- +8.63%
- 2025 vs 2024
- Net income growth
- +45.34%
- 2025 vs 2024
- Net margin
- 17.4%
- 2024: 13.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14,575 | 11,861 | 10,345 | 9,808 | 5,963 | 4,799 | 2,969 | 2,618 | 3,578 | 4,145 |
| Depreciation and amortization | 5,392 | 4,981 | 4,851 | 5,178 | 4,039 | 2,835 | 2,714 | 2,731 | 2,320 | 2,181 |
| Capital expenditure | -2,810 | -1,924 | -1,361 | -1,091 | -1,091 | -961 | -979 | -1,043 | -1,326 | -1,446 |
| Investing cash flow | -6,808 | -7,980 | -4,064 | -2,960 | -11,058 | -285 | -657 | 963 | -2,328 | -3,969 |
| Financing cash flow | -7,544 | -3,996 | -6,567 | -6,823 | 3,649 | -2,203 | -1,765 | -2,044 | -2,936 | -1,324 |
| Dividends paid | -4,846 | -4,606 | -4,491 | -4,364 | -3,856 | -3,572 | -3,592 | -3,484 | -3,519 | -3,561 |
| Share repurchases | -521 | -81.0 | — | — | — | — | — | — | — | — |
| Debt issued | 379 | 6,492 | 3,977 | 74.0 | 12,929 | 3,256 | 500 | 2,971 | 2,324 | 2,491 |
| Debt repaid | -2,401 | -4,999 | -5,210 | -1,515 | -5,275 | -1,816 | -2,202 | -1,498 | -1,764 | -319 |
| Effect of exchange rates | 46.0 | -93.0 | -60.0 | -80.0 | -62.0 | 12.0 | 5.0 | -38.0 | -66.0 | 21.0 |
| Net change in cash | 269 | -208 | -346 | -55.0 | -1,508 | 2,323 | 552 | 1,499 | -1,752 | -1,127 |
| Free cash flow | 11,765 | 9,937 | 8,984 | 8,717 | 4,872 | — | — | — | — | — |
| Levered free cash flow | 7,865 | 8,461 | 9,040 | 12,485 | -1,845 | 3,441 | 6,213 | 3,698 | 4,195 | 4,476 |